Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib in High Risk Advanced Non-squamous NSCLC
NCT03684967Phase 2Withdrawn
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- May 2018
- Primary completion
- Sep 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Hutchison MediPharma (HMP). Planned start May 2018; status: withdrawn.
02
Drugs
fruquintinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03684967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03684967.